Results 141 to 150 of about 424,058 (165)

Correction: BNT162b2 versus mRNA-1273 Third Dose COVID-19 Vaccine in Patients with CKD and Maintenance Dialysis Patients. [PDF]

Clin J Am Soc Nephrol
europepmc   +1 more source

A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine

Vaccine, 2021
BACKGROUND: Vaccines are urgently needed to prevent the global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We assessed the safety and immunogenicity of vaccine candidate mRNA-1273, encoding the prefusion-stabilized spike ...
Laurence Chu, Roderick Mcphee, Wenmei Huang   +2 more
exaly   +2 more sources

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase [PDF]

New England Journal of Medicine, 2021
BACKGROUND: At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease 2019 (Covid-19).
Hana M El Sahly, Brandon Essink, Judith M Martin   +2 more
exaly   +4 more sources

Comparison of antibody immune responses between BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in naïve and previously infected individuals [PDF]

Journal of Travel Medicine, 2021
Two mRNA vaccines, Pfizer-BNT162b2 and Moderna-mRNA-1273, obtained the Emergency Use Listing by WHO for preventing COVID-19. However, little is known about the difference in antibody responses induced by these two mRNA vaccines in naïve and previously ...
Duaa W Al-Sadeq, Farah M Shurrab, Ahmed Ismail   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Myocarditis After BNT162b2 and mRNA-1273 Vaccination

Circulation, 2021
Kathryn F Larson, Enrico Ammirati, Eric Adler   +2 more
exaly